Abstracts tagged "Outcome measures"

Abstract Number: 2396 • ACR Convergence 2024
PROMISing Outcomes: Understanding the Concordance Between Provider-assessment and Patient-reported Disease Activity in SLE
Anna Korogodina¹, Erin Sundel¹, Yaroslav Markov², Vasileios Kyttaris³, Julianne O'Connell¹ and Suzanne Krishfield¹, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Yale School of Medicine, New Haven, ³BIDMC, Boston, MA
Background/Purpose: SLE-related outcomes are traditionally assessed by clinician-derived measures. However, these assessments often do not fully capture how patients experience their disease. We assessed the alignment…
Abstract Number: 0245 • ACR Convergence 2024
The Impact of COVID-19 and ‘Long COVID’ on Self-Reported Disease Activity, Disability, and Quality of Life in Patients with Inflammatory Arthritis
Zachary Wallace¹, Miao Lin², Shruthi Srivatsan², Andrew King², Xiaosong Wang³, Rathnam Venkat⁴, Naomi Patel², Yumeko Kawano⁵, Abigail Schiff⁵, Jennifer Hanberg², Emily Kowalski⁵, Colebrook Johnson², Kathleen Vanni³, Zachary Williams², Grace Qian³, Caleb Bolden², Kevin Mueller⁵, Katarina Bade⁵, Alene Saavedra⁵ and Jeffrey Sparks⁶, ¹Massachusetts General Hospital, Newton, MA, ²Massachusetts General Hospital, Boston, MA, ³Brigham and Women’s Hospital, Boston, MA, ⁴Tufts University School of Medicine, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: People with rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile idiopathic arthritis (JIA), and axial spondyloarthritis (axSpA) are at risk for poor COVID-19 outcomes, including…
Abstract Number: 0409 • ACR Convergence 2024
Differences in Clinical Presentation and Outcomes Between Down Syndrome-Associated Arthritis and Juvenile Idiopathic Arthritis
Irene Chern¹, Jade Singleton², Xing Wang³ and Jordan Jones⁴, ¹St. Christopher's Hospital for Children, Philadelphia, PA, ²Seattle Children's Hospital, Seattle, ³Biostatistics Epidemiology and Analytics in Research, Seattle Children’s Research Institute, Seattle, WA, ⁴Children's Mercy Kansas City, Kansas City, MO
Background/Purpose: Down syndrome (DS), a disorder caused by triplication of chromosome 21, affects around 1 in 1000 births making it one of the most common…
Abstract Number: 0629 • ACR Convergence 2024
Evaluating the Concordance Between SRI4 and BICLA Using Placebo Data from Randomized Controlled Trials of Patients with Active Systemic Lupus Erythematosus
Anca Askanase¹, Edward Vital², Oliver Meier³, Armando Turchetta⁴, Huiyan (Ashley) Mao⁴, Justine Maller⁵, Jorge A. Ross Terres⁶ and Maria Dall'Era⁷, ¹Columbia University Medical Center, New York, NY, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, Leeds, England, United Kingdom, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland, ⁴Hoffmann-La Roche Ltd, Mississauga, Canada, ⁵Genentech, Inc,, San Francisco, CA, ⁶Genentech, Inc,, San Francisco, ⁷UCSF, Corte Madera, CA
Background/Purpose: British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) and Systemic Lupus Erythematosus Responder Index 4 (SRI4) responses are the most common primary…
Abstract Number: 0791 • ACR Convergence 2024
Optimizing Knee Osteoarthritis Treatment with the Precision Medicine Approach in a Clinical Trial Dataset
Caroline Walton¹, Forrest Hurley², Liubov Arbeeva³, Stephen Messier⁴, Shannon Mihalko⁴, Jeffrey Katz⁵, Richard Loeser⁶, David Hunter⁷, Leigh Callahan⁸ and Amanda Nelson², ¹UNC School of Medicine, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³University of North Carolina, Chapel Hill, Carrboro, NC, ⁴Wake Forest University, Winston Salem, NC, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶University of North Carolina, Chapel Hill, NC, ⁷Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, ⁸University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC
Background/Purpose: Precision medicine has previously identified subgroups of clinical trial participants with knee osteoarthritis (kOA) that benefit more from a specific intervention than others. We…
Abstract Number: 1126 • ACR Convergence 2024
The Outcomes of Carpal Tunnel Injections and Carpal Tunnel Surgery
wilmer sibbitt¹, dihowm Fatma¹, N. SUZANNE Emil¹, Maheswari Muruganandam², Roderick A Fields¹, Vangala Adarsh¹, Frank O'Sullivan³, Shuhei Hattori⁴, Frank M Delgado¹ and Krystle Tapia¹, ¹UNM, Albuquerque, NM, ²University of New Mexico, Albuquerque, NM, ³University of New Mexico School of Medicine, Albuquerque, NM, ⁴University of Hawaii, Hawaii
Background/Purpose: arpal tunnel syndrome (CTS) is the most common peripheral neuropathy secondary to chronic median nerve compression at the wrist within the space-limited carpal tunnel…
Abstract Number: 1468 • ACR Convergence 2024
Efficacy of bDMARDs in Early versus Established Disease in Axial Spondyloarthritis: A Meta-Analysis of Randomized Trials
Diego Benavent¹, Victoria Navarro Compán², Dafne Capelusnik³ and Sofia Ramiro⁴, ¹Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Spain, CAMBRILS, Spain, ²La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ³Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁴Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: The ASAS consensus definition of ‘early axial spondyloarthritis (axSpA)’ (axial symptoms ≤ 2 years) was expert-based given the scarcity of evidence1. We conducted a…
Abstract Number: 1699 • ACR Convergence 2024
Anakinra in Giant Cell Arteritis: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
Hubert de Boysson¹, Kim Ly², Loik Geffray³, Thomas Quemeneur⁴, Eric Liozon⁵, Holy Bezanahary⁵, Noemie Le Gouellec⁴, Alexandra Audemard⁶, Samuel Deshayes⁷, Jonathan Boutemy⁸, Gwénola Maigné⁸, Nicolas Martin Silva⁸, Jean-Jacques Parienti⁸ and Achille Aouba⁷, ¹Caen university Hospital, Caen, France, ²CHU Limoges, limo, France, ³CH Lisieux, Lisieux, France, ⁴CH Valenciennes, Valenciennes, France, ⁵CHU Limoges, Limoges, France, ⁶Tours, Tours, France, ⁷Service d'immunologie clinique-médecine interne, CHU de Caen Normandie, Caen, France, ⁸CHU Caen, Caen, France
Background/Purpose: A previous retrospective series reported the efficacy and tolerance of anakinra (ANK) in giant cell arteritis (GCA) and called for further validation in a…
Abstract Number: 2197 • ACR Convergence 2024
Outcome Measures for the Assessment of Cutaneous and Musculoskeletal Manifestations of Juvenile Systemic Sclerosis: An International Collaborative Scoping Review and Survey of Current Practice
Amanda Robinson¹, Mustafa Çakan², Simone Appenzeller³, Susan Shenoi⁴, Meiping Lu⁵, Betul Sozeri⁶, Rongjun Zheng⁵, Priya Bhave⁷, Natalia Vasquez Canizares⁸ and Suzanne Li⁹, and International Juvenile Systemic Sclerosis Outcomes Group (IJOG), ¹Division of Pediatric Rheumatology, University of Utah, Salt Lake City, UT, ²Clinic of Pediatric Rheumatology, Zeynep Kamil Women and Children's Diseases Training and Research Hospital, İstanbul, Turkey, ³Unicamp, Campinas, SP, Brazil, ⁴Seattle Children's Hospital and Research Center, Mercer Island, WA, WA, ⁵Department of Rheumatology Immunology and Allergy, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China (People's Republic), ⁶University of Health Sciences, Istanbul, Turkey, ⁷Hackensack Meridian School of Medicine, Hackensack, NJ, ⁸Children's Hospital at Montefiore; Albert Einstein College of Medicine;, New York, NY, ⁹Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, Hackensack, NJ
Background/Purpose: Juvenile systemic sclerosis (jSSc) is a rare fibrosing autoimmune disease associated with significant morbidity and mortality. Data on treatment strategies is limited, primarily based…
Abstract Number: 2402 • ACR Convergence 2024
Belimumab Reduces Disease Flares versus Placebo in Adults with Early Active Systemic Lupus Erythematosus: Results of a Large Integrated Analysis
Marta Mosca¹, Karen Costenbader², Joan Merrill³, Holly Quasny⁴, Christine Henning⁵, Steven Bloom⁶, Julia Harris⁶, Ciara O’Shea⁷, Tatsuya Atsumi⁸ and Ronald Van Vollenhoven⁹, ¹University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, ²Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ³Oklahoma Medical Research Foundation, Oklahoma City 73104, OK, ⁴GSK, Clinical Sciences, Durham, NC, ⁵GSK, Global Medical Affairs, Durham, NC, ⁶GSK, Immunology Biostatistics, Brentford, United Kingdom, ⁷GSK, Rheumatology, Global Medical Affairs, Dublin, Ireland, ⁸Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ⁹Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: SLE flares are associated with increased risk of organ damage/mortality; flare prevention is a key treatment goal.1 Initiating treatment earlier has benefits in autoimmune…
Abstract Number: 0261 • ACR Convergence 2024
Clinical Implications, Bacterial Profiles, and Patient Outcomes in Hospitalized Patients with Autoimmune Rheumatic Diseases
Angel Kevin Garza-Elizondo¹, Ana Cecilia Bardan-Inchaustegui², Pablo Gamez-Siller³, Diana Elsa Flores-Alvarado⁴, Jorge Esquivel-Valerio⁵, Jesus Cardenas-de la Garza², Elsa Catalina Davila-Correa⁶, Alejandra Jacquelin Osuna-Corrales⁶, Karla Judith Duran-Villarreal⁶, Daniela Alejandra Salcedo-Soto⁷, Derek de Jesus Gauna-Leal⁶, Andrea Axelle Prado-Prado⁶, Debanhi Morales-Espronceda⁶, Nathalia Valdez-Benavides⁶, Nirvana Amairany González-Ontiveros⁶ and Dionicio Galarza-Delgado⁸, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, ²Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ³Facultad de Medicina UANL, Monterrey, Nuevo León, Mexico, ⁴Hospital Universitario Jose Eleuterio Gonzalez, Monterrey, Nuevo León, Mexico, ⁵Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, ⁶Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Mexico, ⁷Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico, ⁸UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Autoimmune rheumatic diseases (ARD) are chronic conditions that affect multiple organ systems. Patients with ARD tend to have a weak immune system due to…
Abstract Number: 0496 • ACR Convergence 2024
Dissecting Early RA Patient Trajectories Through Time-independent Disease State Identification Identifies Distinct Patterns Dissected by Inflammation in Blood or Joints
Nils Steinz¹, Tjardo Maarseveen², Andrew Cope³, John Isaacs⁴, Aaron Winkler⁵, Thomas Huizinga⁶, Yann Abraham⁷ and Rachel Knevel¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Leiden University Medical Center, Wormerveer, Netherlands, ³King's College London, London, United Kingdom, ⁴Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ⁵Pfizer Inc., Cambridge, MA, ⁶Department of Rheumatology, Leiden University, Leiden, Netherlands, ⁷Janssen Research and Development, Beerse, Belgium
Background/Purpose: Patients with RA display different trajectories in the improvement of disease activity. Discerning the RA trajectories, how they differ between patients and which factors…
Abstract Number: 0632 • ACR Convergence 2024
Cutaneous Lupus Erythema and Scale Have Similar Six-month Trends Without Significant Impact from Race/ethnicity or Disease Subtype
Tyler Cepica¹, Lillian Xie², Daniella Faden², Caroline Stone³, Victoria Werth⁴ and Benjamin Chong⁵, ¹University of Texas Southwestern Medical School, Benbrook, TX, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Phiiladelphia, PA, ⁴Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵The University of Texas Southwestern Medical Center, Department of Dermatology, Dallas, TX
Background/Purpose: The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated outcome measure designed to assess cutaneous lupus erythematosus (CLE) activity (CLASI-A)…
Abstract Number: 0796 • ACR Convergence 2024
Development and Evaluation of Machine Learning Prediction Models for Hospitalizations Due to Opioid-Related Harms Among New Users with Rheumatic and Musculoskeletal Diseases
Carlos Raul Ramirez Medina¹, Mark Lunt², David Jenkins², William Dixon², Niels Peek³ and Meghna Jani², ¹The University of Manchester, Warrington, United Kingdom, ²University of Manchester, Manchester, United Kingdom, ³THIS Institute , University of Cambridge, Cambridge, United Kingdom
Background/Purpose: England has seen a notable rise in prescription opioid use over the past two decades, leading to some of Europe's highest opioid-related hospital admissions.…
Abstract Number: 1135 • ACR Convergence 2024
Deucravacitinib in Plaque Psoriasis: 4-Year Efficacy Results by Prior Biologic Treatment in the Phase 3 POETYK PSO-1, PSO-2, and Long-Term ExtensionTrials
Richard Warren¹, April W. Armstrong², Shinichi Imafuku³, Akimichi Morita⁴, Carle Paul⁵, Matthias Augustin⁶, Thierry Passeron⁷, Leon Kircik⁸, Eleni Vritzali⁸, Thomas Scharnitz⁹, Georgene Schroeder⁹, Subhashis Banerjee¹⁰ and Bruce Strober¹¹, ¹Dermatology Centre, Northern Care Alliance NHS Foundation Trust and NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²University of California Los Angeles, Los Angeles, ³Fukuoka University Hospital Faculty of Medicine, Fukuoka, Japan, ⁴Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁵Toulouse University and CHU, Toulouse, France, ⁶Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁷Université Côte d’Azur, University Hospital of Nice, Nice, France, ⁸Icahn School of Medicine at Mount Sinai, New York, NY, ⁹Bristol Myers Squibb, Princeton, ¹⁰Bristol Myers Squibb, Princeton, NJ, ¹¹Department of Dermatology, Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell, CT
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].